Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Tranexamic Acid in MI-TLIF
NCT06427850Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in spinal stenosis, intervertebral disc degeneration (DDD) and spondylolisthesis comparing Topical TXA with Placebo (2 arms). Primary endpoint: Postoperative drainage at 120 hours. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tranexamic acid
03
Conditions
spinal stenosisintervertebral disc degeneration (DDD)spondylolisthesis
Beyond the preview
Go deeper on NCT06427850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427850.